Maxcyte (MXCT) Research & Development (2020 - 2026)

Maxcyte (MXCT) has 7 years of Research & Development data on file, last reported at $3.9 million in Q1 2026.

• On a quarterly basis, Research & Development fell 34.66% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $18.9 million, a 4.67% decrease from a year earlier, with the FY2025 full-year figure at $18.9 million, down 14.86% from the prior year.
• Research & Development for Q1 2026 stood at $3.9 million, up from $3.5 million in the prior quarter.
• Over the last five years, Research & Development for MXCT reached as high as $7.4 million in Q1 2024 and fell as low as $2.0 million in Q4 2024.
• Historically, Research & Development has averaged $5.2 million across 5 years, with a median of $5.3 million in 2022.
• Across the five-year window, Research & Development soared 487.02% in 2022 and slumped 49.52% in 2024, its largest moves.
• Year by year, Research & Development stood at $5.7 million in 2022, then fell by 29.48% to $4.0 million in 2023, then slumped by 49.52% to $2.0 million in 2024, then jumped by 71.85% to $3.5 million in 2025, then climbed by 10.07% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $3.9 million in Q1 2026, $3.5 million in Q4 2025, and $5.3 million in Q3 2025.